Si deseas distinguir tus productos, servicios o ambos de los de otra empresa, es posible que necesites una marca o nombre comercial. Descubre qué son, en qué consiste su procedimiento de registro y qué implica.
Información sobre los plazos de presentación de solicitudes de transformación de marcas de la Unión Europea en marca nacional española. Más información
Si tienes un nuevo dispositivo, producto o procedimiento que resuelva un problema técnico o tenga una ventaja práctica, existen distintas formas de protegerlo en España y en otros países. Descubre cómo hacerlo.
¿Tu innovación reside en la estética, la ornamentación o la apariencia de tu producto? Protégela mediante un diseño industrial. Descubre qué derechos confiere el registro y cómo realizar la tramitación.
Las indicaciones geográficas protegen el nombre de un producto originario de una zona geográfica, a la cual le debe una determinada calidad, reputación u otra característica. Descubre qué son, en qué consiste su procedimiento de registro y qué beneficios conceden.
Las patentes publicadas en todo el mundo son una valiosa fuente de información científica, técnica y comercial.
Si eres emprendedor/a o una empresa y quieres potenciar y mejorar la rentabilidad de tu negocio protegiendo de forma adecuada los activos intangibles de tu organización, en este espacio encontrarás lo necesario.
131
resultados
Última actualización
25/04/2026 [07:24:00]
Resultados 100 a 125 de 131
Resumen de: WO2026050519A2
The present invention provides nucleic acid molecules and methods that use miRNA sequences that knocking down mRNA for the human DNA mismatch repair protein MutS Homolog 3 (MSH3), thereby resulting in the treatment of Huntington's Disease.
Resumen de: US20260061011A1
A Bifidobacterium animalis subsp. lactis for reducing Abeta42 deposition and an application, a name of the Bifidobacterium animalis subsp. lactis is Bifidobacterium animalis subsp. lactis IOB-LO7, and classified as Bifidobacterium animalis subsp. lactis, the Bifidobacterium animalis subsp. lactis IOB-LO7 is preserved in the General Microbiology Center of the China General Microbiological Culture Collection Center (CGMCC) on Dec. 23, 2021, with the collection number of CGMCC No. 24185. By reducing the levels of Aβ42 in the cerebral cortex and hippocampus, clearing Aβ amyloid plaques, improving communication between neurons, reducing brain neuroinflammation, and protecting nerve cells, it helps to restore cognitive function and improve Alzheimer's disease. Additionally, it can also improve gut microbiota imbalance caused by Alzheimer's disease.
Resumen de: WO2026047040A1
The present invention relates to a compound of formula (I) wherein R1 is a hydrogen atom, halogen or -(C1-C2)alkyl, R2 is -halo(C1-C2)alkoxy, and R3 and R4 form together with N to which they are attached an optionally substituted 5-7 membered monocyclic heterocycloalkyl ring or an optionally substituted 8-11 membered bicyclic heterocycloalkyl ring. The present invention also relates to a medicament and a pharmaceutical composition comprising said compound of formula (I), as well as their therapeutic uses, in particular as inhibitor of NOD-like receptor protein 3 inflammasome for preventing and/or treating Parkinson's disease, frontotemporal Dementia, Multiple System Atrophy, Alzheimer's disease, Multiple Sclerosis, Amyotrophic Lateral Sclerosis or brain injury.
Resumen de: AU2024345495A1
The disclosure pertains to treating a cognitive impairment, for example, an aging-associated cognitive impairment. In certain aspects, the disclosure describes methods of assaying a sample obtained from a subject having or suspected of having a cognitive impairment for one or more proteins selected from: DLL1, VNN2, VAV3, and SUMF1. In certain embodiments, the cognitive impairment is caused by a neurodegenerative disease, such as Alzheimer's disease. The methods further comprise identifying a subject as likely or not likely to respond positively to the plasma exchange therapy. In even further aspects, the disclosure describes methods for treating a cognitive impairment in the subject by a plasma exchange therapy, wherein based on the specific protein expression data, the subject is identified as likely or not likely to respond positively to the plasma exchange therapy. The plasma exchange therapy can be full and/or low volume plasma exchange. Also provided are kits suitable for performing the methods disclosed herein.
Resumen de: US20260060947A1
This invention relates to the use of nitroalkene derivatives for the treatment of neurodegenerative conditions in mammals in which neuroinflammation is a contributing factor, such as in amyotrophic lateral sclerosis (ALS).
Resumen de: US20260062413A1
Provided are compounds that are kinase inhibitors. The compounds have improved properties that lead to specific targeting of kinases without inhibiting the activity of related enzymes, which make them useful for therapeutic intervention in a variety of disorders and disease in which inhibition of the kinase can be clinically useful, e.g., Alzheimer's disease and other neurodegenerative diseases. The compounds can also be used in methods of treating a neurodegenerative disease associated with inflammation, such as Alzheimer's disease, Huntington's disease, Parkinson's disease, epilepsy, stroke, amyotrophic lateral sclerosis (ALS), spinal muscular atrophy (SMA), or a disease or disorder such as deafness, glaucoma, organ failure, or cancers, including, but not limited to, those susceptible to combination therapy with epigenetic targets such as those associated with bromodomain (BRD) proteins, histone deacetylases (HDACs), and the like.
Resumen de: AU2026201203A1
Compounds described herein may be used for the treatment of neurodegenerative diseases linked to protein misfolding, including prion diseases, Alzheimers' disease, Parkinson's disease (PD) and amyotrophic lateral sclerosis (ALS), and also other neurodegenerative, degenerative, metabolic and ischemic conditions. Indeed, NAD metabolism impairment is also a critical feature in brain ischemia/reperfusion injury, Wallerian degeneration, kidney failure, multiple sclerosis, aging, and metabolic disorders such as diabetes mellitus. Therapies that elevate or stabilize NAD levels may thus have broad potential for treating many severely debilitating neurological and metabolic conditions. Evidence is provided herein with compounds from 8 lead series for NAD restoring properties and for therapeutic efficacy in cellular and/or animal models of prion disease, PD and ALS. eb e b
Resumen de: US20260061034A1
Methods for preventing or treating brain neuronal diseases are provided. The methods include administering mesenchymal stem cells having increased agouti-related peptide (AgRP) expression or a conditioned medium thereof to a subject in need thereof. In some embodiments, the conditioned medium contains AgRP. The methods may further comprise administering ghrelin. The brain neuronal diseases include Alzheimer's disease, frontotemporal dementia, tauopathy, Parkinson's disease, amyotrophic lateral sclerosis, Huntington's disease, multiple sclerosis, stroke, thrombosis, embolism, head trauma, cerebral circulatory or metabolic disorders, brain dysfunction, and dementia.
Resumen de: US20260062389A1
Provided herein are optionally substituted benzoimidazol-1,2-yl amides, pharmaceutical compositions comprising a therapeutically effective amount of such compounds and a pharmaceutically acceptable excipient, and methods of treating Kv7 associated diseases, such as, epilepsy, amyotrophic lateral sclerosis, various types of pain, hyperexcitability, a dyskinesia, dystonia, mania and tinnitus with such compounds and pharmaceutical compositions.
Resumen de: US20260062497A1
Provided are pharmaceutical formulations and dosing regimen for antibody-based treatment of amyotrophic lateral sclerosis (ALS).
Resumen de: EP4702978A1
An agent for treating or preventing amyotrophic lateral sclerosis, wherein an active component of the agent essentially consists of at least one selected from the group consisting of cycloserine, terizidone, and salts thereof. The active component may consist of at least one selected from the group consisting of cycloserine, terizidone, and salts thereof. The cycloserine may be D-cycloserine. The cycloserine may be L-cycloserine.
Resumen de: EP1000000A1
The invention relates to an apparatus (1) for manufacturing green bricks from clay for the brick manufacturing industry, comprising a circulating conveyor (3) carrying mould containers combined to mould container parts (4), a reservoir (5) for clay arranged above the mould containers, means for carrying clay out of the reservoir (5) into the mould containers, means (9) for pressing and trimming clay in the mould containers, means (11) for supplying and placing take-off plates for the green bricks (13) and means for discharging green bricks released from the mould containers, characterized in that the apparatus further comprises means (22) for moving the mould container parts (4) filled with green bricks such that a protruding edge is formed on at least one side of the green bricks.
Resumen de: EP1000000A1
The invention relates to an apparatus (1) for manufacturing green bricks from clay for the brick manufacturing industry, comprising a circulating conveyor (3) carrying mould containers combined to mould container parts (4), a reservoir (5) for clay arranged above the mould containers, means for carrying clay out of the reservoir (5) into the mould containers, means (9) for pressing and trimming clay in the mould containers, means (11) for supplying and placing take-off plates for the green bricks (13) and means for discharging green bricks released from the mould containers, characterized in that the apparatus further comprises means (22) for moving the mould container parts (4) filled with green bricks such that a protruding edge is formed on at least one side of the green bricks.
Resumen de: US20260099855A1
0000 Systems and methods are provided for authenticating, verifying, and tracking physical and digital assets through an integrated framework combining artificial intelligence, multi-sensor fusion, blockchain provenance, and quantum-secure processing. The system establishes a continuous provenance loop where real-time live capture, multi-sensor scanning, and expanded identifiers are analyzed by an AI decision engine to generate a unique multi-modal fingerprint. 0000 This fingerprint is encoded into one or more machine-readable identifiers immutably recorded on a blockchain ledger. A Genesis Certificate of Authenticity (COA) anchors the item's origin, ownership, and transfer history. Subsequent resales or transfers trigger smart contracts that automate royalty distribution and provenance updates. The value captured through these processes can be monetary, such as currency or royalties, or intrinsic, such as positive social impact derived from verified actions or good deeds. Quantum acceleration enhances pattern matching, anomaly detection, and cryptographic resilience across industries.
Resumen de: US20260099855A1
0000 Systems and methods are provided for authenticating, verifying, and tracking physical and digital assets through an integrated framework combining artificial intelligence, multi-sensor fusion, blockchain provenance, and quantum-secure processing. The system establishes a continuous provenance loop where real-time live capture, multi-sensor scanning, and expanded identifiers are analyzed by an AI decision engine to generate a unique multi-modal fingerprint. 0000 This fingerprint is encoded into one or more machine-readable identifiers immutably recorded on a blockchain ledger. A Genesis Certificate of Authenticity (COA) anchors the item's origin, ownership, and transfer history. Subsequent resales or transfers trigger smart contracts that automate royalty distribution and provenance updates. The value captured through these processes can be monetary, such as currency or royalties, or intrinsic, such as positive social impact derived from verified actions or good deeds. Quantum acceleration enhances pattern matching, anomaly detection, and cryptographic resilience across industries.
Resumen de: MX2025014476A
The present invention relates to a pharmaceutical composition comprising crisdesalazine or a salt thereof, which has improved stability by reducing the content of related substances of crisdesalazine, and has an increased dissolution rate by improving the intrinsic solubility thereof. The composition of the present invention secures stability and bioavailability, and thus is more effective in treating neurodegenerative diseases (Alzheimer's disease, Parkinson's disease, amyotrophic lateral sclerosis, Huntington's disease, epilepsy accompanied by free radical neurotoxicity, cerebral trauma, spinal injury, and the like), inflammatory diseases (gastritis, colitis, pancreatitis, arthritis, diabetic inflammation, inflammatory bowel disease, nephritis, hepatitis, arteriosclerosis inflammation, and the like), stress disorders (anxiety disorder, depression, and the like), and the like.
Resumen de: MX2026000096A
The invention relates to liposome-encapsulated apomorphine, processes for preparing said liposome-encapsulated apomorphine and to the use of such in the treatment of Parkinson's disease.
Resumen de: MX2025011198A
Provided herein are compositions and methods for the treatment of neuroinflammatory diseases and conditions, including Alzheimer's disease (AD), Parkinson's disease (PD), amyotrophic lateral sclerosis (AES), multiple sclerosis (MS), traumatic brain injury (TBI), complex regional pain syndrome (CRPS), optic neuritis (ON), neuromyelitis optica (NMO), chronic traumatic encephalopathy (CTE), ischemic stroke (IS), Vascular dementia (VAD), Anti- myelin oligodendrocyte glycoprotein antibody disease (MOGAD), Transverse myelitis (TM), Autoimmune Encephalitis (AE), Acute disseminated encephalomyelitis (ADEM), Chronic meningitis (CM), Central nervous system (CNS) vasculitis, Hashimoto's encephalitis (HE), Neurosarcoidosis (NS), Multiple system atrophy (MSA), Migraine, Chemotherapy-induced pain or Dementia-related pain.
Resumen de: MX2025012556A
Novel compositions of N-desmethyl ruboxistaurin L-lactate. The use of compositions of N-desmethyl ruboxistaurin L-lactate to modulate GSK-3 signaling is disclosed, as is the use of compositions of N-desmethyl ruboxistaurin L-lactate to inhibit protein kinase C. Methods are also disclosed of using compositions of N-desmethyl ruboxistaurin L-lactate in the treatment of subjects having a neurological disease and/or psychiatric disorder, including Alzheimer's disease, bipolar disorder, depression, schizophrenia, Parkinson's disease, or neuroinflammation, as well as methods of using compositions of N-desmethyl ruboxistaurin L-lactate in treating conditions associated with diabetes mellitus or its complications, or ischemia, inflammation, pulmonary hypertension, congestive heart failure, cardiovascular disease, dermatological disease, or cancer. In addition, compositions of N-desmethyl ruboxistaurin L-lactate administered in combination with lithium or other treatments for bipolar disorder are also disclosed.
Resumen de: NZ772009A
Disclosed are methods of treating Alzheimer’s Disease by administering to a patient in need thereof a riluzole prodrug such as troriluzole. Pharmaceutical compositions and kits including the riluzole prodrugs are also disclosed.
Resumen de: CN121574275A
The invention discloses a method for extracting and preparing an oligosaccharide extract from codonopsis pilosula and application of the oligosaccharide extract in prevention and treatment of neurodegenerative disease Alzheimer's disease, and belongs to the technical field of traditional Chinese medicine pharmacy. According to the present invention, the oligosaccharide extract is enriched and prepared from Codonopsis pilosala (Franch.) Nanf., wherein the Codonopsis pilosala (Franch.) Nanf. Is a plant of the family of Platycodon grandiflorum, and the activity test of the oligosaccharide extract on the improvement of cognitive dysfunction in the animal body is performed; results show that in a mouse cognitive function impairment model caused by sleep deprivation, the high-dose codonopsis pilosula oligosaccharide has a prominent effect on improving the learning and memory ability of a Morris water maze and a neuroprotective effect, the efficacy of the codonopsis pilosula oligosaccharide is equivalent to that of a positive control drug manntranet, and no obvious toxic or side effect is found. The codonopsis pilosula oligosaccharide is expected to be further developed into functional food, health care products and/or medicines with the effect of preventing and/or improving cognitive impairment.
Resumen de: CN121570448A
The invention discloses application of glutaric acid or medicinal salt thereof in medicine, a medicine composition and a medicine preparation, and belongs to the field of medicine application. According to the application of the glutaric acid or the medicinal salt thereof in preparing the medicine for inhibiting neurodegeneration, promoting lysosomal activity and treating the Alzheimer's disease, a new potential treatment medicine is provided for treatment of the Alzheimer's disease, and a more effective scheme for treating the Alzheimer's disease is provided.
Resumen de: CN121570577A
The invention relates to application of insulin and analogues thereof in preparation of medicines for preventing or treating Alzheimer's disease. Researches find that the damage effect of A beta on insulin secretion depends on CX3CR1, the blood plasma insulin level of AD model mice can be recovered by supplementing exogenous insulin, and the A beta has the treatment effects of improving cognitive impairment of AD model mice, improving cerebrovascular lesion, recovering brain glycometabolism function, relieving brain inflammatory response and the like; the invention provides an alternative medicine with definite curative effect, high safety and affordable price for Alzheimer's disease, expands the indications of insulin and analogues thereof, and has wide market prospect and important social significance.
Resumen de: CN121574923A
The invention relates to a construction method of a Parkinson-brain organ and application of the Parkinson-brain organ in Parkinson treatment drug screening. The invention discovers that the brain organ can be simply, conveniently and quickly induced to form a Parkinson-brain organ capable of being used for screening Parkinson treatment drugs by treating the brain organ with MPTP, and a basis is provided for quickly screening the Parkinson treatment drugs. According to the application, the obtained Parkinson-brain organ is applied to screening a proper therapeutic drug from reduced triterpenoids, a good effect of Schinensilactone M in treatment of Parkinson's disease is found, formation of alpha-synuclein oligomers is remarkably reduced, activation of microglial cells and release of related inflammatory factors are effectively inhibited, and the Schinensilactone M can be used for treating Parkinson's disease, so that the Schinensilactone M can be used for treating Parkinson's disease. A new compound selection with a novel structure and a unique action mechanism is provided for prevention and treatment of Parkinson's disease.
Nº publicación: CN121575099A 27/02/2026
Solicitante:
FIRST AFFILIATED HOSPITAL OF GANNAN MEDICAL UNIV
\u8D63\u5357\u533B\u79D1\u5927\u5B66\u7B2C\u4E00\u9644\u5C5E\u533B\u9662
Resumen de: CN121575099A
The invention belongs to the field of biomedicine, and particularly relates to application of miRNA-219a-2-3p in diagnosis and treatment of Parkinson's disease. Relates to application of the reagent in preparation of a Parkinson's disease detection kit. The reagent comprises the following components: (1) miRNA-219a-2-3p or/and a mimic substance thereof; or/and (2) a reagent for detecting the miRNA-219a-2-3p or/and the mimic substance of the miRNA-219a-2-3p. The invention further relates to application of an inhibitor of the miRNA-219a-2-3 in preparation of a medicine for treating the Parkinson's disease. The invention provides a new technical scheme for Parkinson's disease diagnosis and treatment.
BOPI
Sede Electrónica
